More intensive chemotherapy dramatically improves recurrence, survival in younger patients with aggressive lymphoma
Younger patients with diffuse large B-cell lymphoma given a more intensive regimen of chemotherapy combined with rituximab survive significantly longer, and are approximately twice as likely to remain in remission 3 years later, compared with patients given standard chemotherapy treatment plus rituximab, according to an article published Online First in the Lancet.
Over the past decade, combined treatment with the monoclonal antibody rituximab and a standard chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) has substantially improved outcomes in lymphoma patients younger than 60 years. But some patients still relapse after a complete response to treatment, and the optimum chemotherapy regimen to combine with rituximab has yet to be established. Recent studies suggest that intensive chemotherapy (higher doses with shortened intervals between treatments) might benefit younger patients with aggressive lymphomas.
This study, conducted by the Groupe d'Etude des Lymphomes de I'Adulte (GELA), randomly assigned 379 patients aged 18 years with early intermediate-stage diffuse large B-cell lymphoma (one of the most common and aggressive forms of non-Hodgkin's lymphoma) to receive either four cycles of dose-intensive chemotherapy (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) plus rituximab (R-ACVBP)* at 2 week intervals, or eight cycles of the standard treatment (R-CHOP) at 3 week intervals.
After 3 years, event-free survival (patients not experiencing unplanned treatment for lymphoma, disease progression or recurrence, or death) was significantly better for patients in the dose-intensive group compared with those receiving standard treatment (81% vs 67%), with the more intensive chemotherapy reducing the risk of experiencing an event by 44%.
Additionally, patients assigned to the intensified regimen had a 56% lower risk of death and were 52% less likely to experience disease progression compared with those given standard treatment.
But increasing the treatment intensity also significantly increased the likelihood of serious side effects. In particular, haematological and mucosal toxic effects were significantly more common in the dose-intense group, and a much higher proportion of patients experienced febrile neutropenia (38% vs 9%).
The authors say: "Intensified immunochemotherapy with R-ACVBP represents an alternative to R-CHOP to improve survival in patients younger than 60 years with diffuse large B-cell lymphoma of low-intermediate risk."
They conclude by calling for further research to identify subsets of patients who are more likely to benefit from this intensive regimen.
In a Comment, Julie Vose from Nebraska Medical Center, Omaha, USA, cautions: "This dose-intense regimen should only be used in patients in whom the expected relapse rate is sufficient to justify the higher toxic effects and cost profile."
More information: Paper online: www.thelancet.com/… 0-4/abstract
Provided by Lancet
- Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years Dec 09, 2008 | not rated yet | 0
- New treatment approach promising for lymphoma patients in the developing world Jul 06, 2008 | not rated yet | 0
- Newer, more intense chemotherapy with less radiation not more effective against Hodgkin's lymphoma Oct 25, 2010 | not rated yet | 0
- Two targeted therapies likely better than one in patients with aggressive lymphoma May 15, 2009 | not rated yet | 0
- Statins do not interfere with rituximab treatment for lymphomas, study finds Dec 09, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
5 hours ago From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
21 hours ago I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...
Cancer 17 hours ago | not rated yet | 0
(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...
Cancer 17 hours ago | not rated yet | 0 |
A new review finds cancer survivors suffer a diverse and complex set of impairments, affecting virtually every organ system. Writing in CA: A Cancer Journal for Clinicians, Julie Silver, M.D., associate professor at Harvar ...
Cancer 22 hours ago | not rated yet | 0
(AP)—A California doctor has been sentenced to 14 years in federal prison for bilking her patients out of more than $1 million by promising that an herbal supplement could cure late-stage cancer and other diseases.
Cancer 22 hours ago | not rated yet | 0
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...
Cancer May 17, 2013 | not rated yet | 0 |
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
6 hours ago | 5 / 5 (1) | 0
For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests
Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...
7 hours ago | not rated yet | 0 |
(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...
19 hours ago | 3.7 / 5 (3) | 0 |
The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...
18 hours ago | not rated yet | 0 |
In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...
16 hours ago | 3.7 / 5 (3) | 0 |